ProtoKinetix (PKTX) 10-K 10 Mar 22 2021 FY Annual report Financial data

Cover

Cover - USD ($)	12 Months Ended
	Dec. 31, 2021	Jun. 30, 2021	Mar. 09, 2021
Cover [Abstract]
Document Type	10-K
Amendment Flag	false
Document Annual Report	true
Document Transition Report	false
Document Period End Date	Dec. 31, 2021
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2021
Current Fiscal Year End Date	--12-31
Entity File Number	000-32917
Entity Registrant Name	PROTOKINETIX, INCORPORATED
Entity Central Index Key	0001128189
Entity Tax Identification Number	94-3355026
Entity Incorporation, State or Country Code	NV
Entity Address, Address Line One	412 Mulberry Street
Entity Address, City or Town	Marietta
Entity Address, State or Province	OH
Entity Address, Postal Zip Code	45750
City Area Code	740
Local Phone Number	434-5041
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Public Float		$ 0
Entity Common Stock, Shares Outstanding			299,530,151
Auditor Firm ID	731
Auditor Name	DAVIDSON & COMPANY LLP
Auditor Location	Canada

BALANCE SHEETS

BALANCE SHEETS - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Current Assets
Cash	$ 57,568	$ 193,445
Prepaid expenses and deposits (Note 3)	25,995	1,050
Total current assets	83,563	194,495
Intangible assets (Note 4)	362,671	274,686
Total assets	446,234	469,181
Current Liabilities
Accounts payable and accrued liabilities	93,268	44,959
Total liabilities	93,268	44,959
Stockholders' Equity
Common stock, $0.0000053 par value; 500,000,000 common shares authorized; 297,393,485 and 285,955,071 shares issued and outstanding for 2021 and 2020 respectively (Note 7)	1,591	1,531
Additional paid-in capital	45,892,545	43,615,323
Accumulated deficit	(45,541,170)	(43,192,633)
Total stockholders' equity	352,966	424,221
Total liabilities and stockholders' equity	$ 446,234	$ 469,181

BALANCE SHEETS (Parenthetical)

BALANCE SHEETS (Parenthetical) - $ / shares	Dec. 31, 2021	Dec. 31, 2020
Statement of Financial Position [Abstract]
Common Stock, Par or Stated Value Per Share	$ 0.0000053	$ 0.0000053
Common Stock, Shares Authorized		500,000,000
Common Stock, Shares, Outstanding	297,393,485	285,955,071

STATEMENTS OF OPERATIONS

STATEMENTS OF OPERATIONS - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
EXPENSES
Amortization – intangible assets (Note 4)	$ 3,000	$ 3,000
General and administrative	316,995	208,967
Professional fees (Note 8)	160,388	164,489
Research and development	435,872	527,291
Share-based compensation (Notes 5 and 8)	1,413,055	6,740,743
Operating Income (Expenses)	(2,329,310)	(7,644,490)
Net loss for the year	$ (2,329,310)	$ (7,644,490)
Net loss per common share (basic and diluted)	$ 0	$ (0.03)
Weighted average number of common shares outstanding (basic and diluted)	291,865,922	278,598,615

STATEMENT OF STOCKHOLDERS' EQUI

STATEMENT OF STOCKHOLDERS' EQUITY - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Beginning balance, value at Dec. 31, 2019	$ 1,472	$ 36,107,058	$ (35,548,143)	$ 560,387
Beginning balance, Shares at Dec. 31, 2019	275,400,259
Fair value of share-based compensation		6,740,743		6,740,743
Issuance of common stock pursuant to private placement offering	$ 59	767,522		767,581
Issuance of common stock pursuant to private placement offering, Shares	10,554,812
Net loss for the year			(7,644,490)	(7,644,490)
Ending balance, value at Dec. 31, 2020	$ 1,531	43,615,323	(43,192,633)	424,221
Ending balance, Shares at Dec. 31, 2020	285,955,071
Fair value of share-based compensation		1,413,055		1,413,055
Issuance of common stock pursuant to private placement offering	$ 41	569,959		570,000
Issuance of common stock pursuant to private placement offering, Shares	7,668,572
Issuance of common stock pursuant to warrant exercise	$ 17	274,983		275,000
Issuance of common stock pursuant to warrant exercise, Shares	3,214,286
Issuance of common stock pursuant to cashless option exercise	$ 3	(3)
Issuance of common stock pursuant to cashless option exercise, Shares	555,556
Extension of the terms of warrants		19,227	(19,227)
Net loss for the year			(2,329,310)	(2,329,310)
Ending balance, value at Dec. 31, 2021	$ 1,591	$ 45,892,545	$ (45,541,170)	$ 352,966
Ending balance, Shares at Dec. 31, 2021	297,393,485

STATEMENTS OF CASH FLOWS

STATEMENTS OF CASH FLOWS - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
CASH FLOWS USED IN OPERATING ACTIVITIES
Net loss for the year	$ (2,329,310)	$ (7,644,490)
Adjustments to reconcile net loss to cash used in operating activities:
Amortization – intangible assets	3,000	3,000
Fair value of compensatory options granted	1,413,055	6,740,743
Changes in operating assets and liabilities:
Prepaid expenses and deposits	(24,945)	0
Accounts payable and accrued liabilities	48,309	19,439
Net cash used in operating activities	(889,891)	(881,308)
CASH FLOWS USED IN INVESTING ACTIVITIES
Purchase of intangible assets	(90,985)	(70,178)
Net cash used in investing activities	(90,985)	(70,178)
CASH FLOWS FROM FINANCING ACTIVITIES
Issuance of common stock for cash	845,000	767,581
Net cash from financing activities	845,000	767,581
Net change in cash	(135,877)	(183,905)
Cash, beginning of year	193,445	377,350
Cash, end of year	57,568	193,445
Cash paid for interest	0	0
Cash paid for income taxes	0	0
Supplementary information – non-cash transactions:
There were no non-cash financing or investing activities.	$ 0	$ 0

Basis of Presentation _ Going C

Basis of Presentation – Going Concern Uncertainties	12 Months Ended
	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation – Going Concern Uncertainties	Note 1. Basis of Presentation – Going Concern Uncertainties ProtoKinetix, Inc. (the "Company"), a development stage company, was incorporated under the laws of the State of Nevada on December 23, 1999. The Company is a medical research company whose mission is the advancement of human health care. The Company is currently researching the benefits and feasibility of synthesized Antifreeze Glycoproteins ("AFGP") or anti-aging glycoproteins, trademarked AAGP. During the year ended December 31, 2015, the Company acquired certain patents and rights for cash consideration of $ 30,000 (25,000 Euros), as well as additional patent applications for cash consideration of $ 10,000 and 6,000,000 share purchase warrants with a fair value of $ 25,000 (Note 4). The Company's financial statements are prepared consistent with accounting principles generally accepted in the United States applicable to a going concern. The Company has not developed a commercially viable product, has not generated any significant revenue to date, and has incurred losses since inception, resulting in a net accumulated deficit at December 31, 2021. These factors raise substantial doubt about the Company's ability to continue as a going concern. The Company needs additional working capital to continue its medical research or to be successful in any future business activities and continue to pay its liabilities. Therefore, continuation of the Company as a going concern is dependent upon obtaining the additional working capital necessary to accomplish its objective. Management is presently engaged in seeking additional working capital through equity financing or related party loans. In March 2020, the World Health Organization declared coronavirus COVID-19 a global pandemic. This contagious disease outbreak, which has continued to spread, and any related adverse public health developments, has adversely affected workforces, economies, and financial markets globally, potentially leading to an economic downturn. As of the date of this filing, the Company has regained a significant portion of its operational capacity and we continue to move forward with our research goals. Our supply of the patented AAGP® molecule has been manufactured and stored in the United States and we have adequate inventory to carry out the projects currently underway. The Company engages contract research organizations (CROs) located in both the United States and Canada. The CROs contracted by the Company for research projects have been able to meet milestone goals without disruption due to the pandemic. We cannot predict future disruptions to the Company which may occur due to the spread of COVID-19. We continue to monitor the status of the pandemic and will adjust our strategy accordingly in order to mitigate the impact on our research projects. The accompanying financial statements do not include any adjustments to the recorded assets or liabilities that might be necessary should the Company fail in any of the above objectives and is unable to operate for the coming year.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 2. Summary of Significant Accounting Policies Basis of Presentation The accompanying financial statements have been prepared by the Company in accordance with accounting principles generally accepted in the United States of America ("US GAAP") and are expressed in United States dollars. Use of Estimates Preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. The more significant accounting estimates inherent in the preparation of the Company's financial statements include estimates as to valuation of equity- related instruments issued, deferred income taxes and the useful life and impairment of intangible assets. Cash Cash consists of funds held in checking accounts. Cash balances may exceed federally insured limits from time to time. Fair Value of Financial Instruments Financial instruments, which includes cash, accounts payable and accrued liabilities are carried at amortized cost, which management believes approximates fair value due to the short-term nature of these instruments. The Company measures the fair value of financial assets and liabilities pursuant to ASC 820 "Fair Value Measurements and Disclosures" which defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements. ASC 820 establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The policy describes three levels of inputs that may be used to measure fair value: Level 1 – quoted prices in active markets for identical assets or liabilities. Level 2 – quoted prices for similar assets and liabilities in active markets or inputs that are observable. Level 3 – inputs that are unobservable (for example cash flow modeling inputs based on assumptions). At December 31, 2021, there were no other assets or liabilities subject to additional disclosure. Income Taxes The Company accounts for income taxes following the assets and liability method in accordance with the ASC 740 "Income Taxes." Under such method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. The Company applies the accounting guidance issued to address the accounting for uncertain tax positions. This guidance clarifies the accounting for income taxes, by prescribing a minimum recognition threshold a tax position is required to meet before being recognized in the financial statements as well as provides guidance on derecognition, measurement, classification, interest and penalties, accounting in interim periods, disclosure and transition Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years that the asset is expected to be recovered or the liability settled. Intangible assets – patent and patent application costs The Company owns intangible assets consisting of certain patents and patent applications. Intangible assets acquired separately are measured on initial recognition at cost. Following initial recognition, intangible assets are carried at cost less any accumulated amortization and any accumulated impairment losses. Subsequent expenditures are capitalized only when they increase the future economic benefits embodied in the specific asset to which they relate. All other expenditures are recognized in profit or loss as incurred. As at December 31, 2021, the Company does not hold any intangible assets with indefinite lives. Intangible assets with finite lives are amortized over the useful economic life and assessed for impairment whenever there is an indication that the intangible asset may be impaired. The amortization method and amortization period of an intangible asset with a finite life is reviewed at least annually. Changes in the expected useful life or the expected pattern of consumption of future economic benefits embodied in the asset is accounted for by changing the amortization period or method, as appropriate, and are treated as changes in accounting estimates. Amortization is recognized in profit or loss on a straight-line basis over the estimated useful lives of the Company's patents, whereas no amortization has been recognized on the patent application costs at December 31, 2021. Research and Development Costs Research and development costs are expensed as incurred. Loss per Share and Potentially Dilutive Securities Basic loss per share is computed by dividing the net loss available to common stockholders by the weighted average number of common shares outstanding in the period. Diluted loss per share takes into consideration common shares outstanding (computed under basic earnings per share) and potentially dilutive securities. The effect of 84,690,000 stock options (December 31, 2020 – 82,650,000 ) and 12,081,143 warrants (December 31, 2020 – 10,326,857 ) were not included in the computation of diluted earnings per share for all periods presented because it was anti-dilutive due to the Company's losses. Share-Based Compensation The Company has granted warrants and options to purchase shares of the Company's common stock to various parties for consulting services. The fair values of the warrants and options issued have been estimated using the Black-Scholes Option Pricing Model. The Company accounts for stock compensation with persons classified as employees for accounting purposes in accordance with ASC 718 "Compensation – Stock Compensation", which recognizes awards at fair value on the date of grant and recognition of compensation over the service period for awards expected to vest. Cliff Vesting is used and awards vest on the last day of the vesting period. The fair value of stock options is determined using the Black-Scholes Option Pricing Model. The fair value of common shares issued for services is determined based on the Company's stock price on the date of issuance. Share-based compensation for non-employees in exchange for goods and services used or consumed in an entity’s own operations are also recorded at fair value on the measurement date and accounted for in accordance with ASC 718. The measurement of share-based compensation is subject to periodic adjustment as the underlying instruments vest. The fair value of stock options is estimated using the Black-Scholes Option Pricing Model and the compensation charges are amortized over the vesting period. Common stock Common stock issued for non-monetary consideration are recorded at their fair value on the measurement date and classified as equity. The measurement date is defined as the earliest of the date at which the commitment for performance by the counterparty to earn the common shares is reached or the date at which the counterparty's performance is complete. Transaction costs directly attributable to the issuance of common stock, units and stock options are recognized as a deduction from equity, net of any tax effects. Related Party Transactions A related party is generally defined as (i) any person that holds 10% or more of the Company's securities and their immediate families, (ii) the Company's management, (iii) someone that directly or indirectly controls, is controlled by or is under common control with the Company, or (iv) anyone who can significantly influence the financial and operating decisions of the Company. A transaction is considered to be a related party transaction when there is a transfer of resources or obligations between related parties. Recent Accounting Pronouncements In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (“ASU 2019-12”), which simplifies the accounting for income taxes by removing certain exceptions related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The new ASU also simplifies aspects of the accounting for franchise taxes and enacted changes in tax laws or rates. These changes aim to improve the overall usefulness of disclosures to financial statement users and reduce unnecessary costs to companies when preparing the disclosures. The guidance was effective for the Company beginning on January 1, 2021 and prescribes different transition methods for the various provisions. The adoption of ASU 2019-12 did not have a material impact on the Company’s financial statements and related disclosures. Other than the above, the Company has determined that other significant newly issued accounting pronouncements are either not applicable to the Company’s business or that no material effect is expected on the financial statements as a result of future adoption.

Prepaid Expenses and Deposits

Prepaid Expenses and Deposits	12 Months Ended
	Dec. 31, 2021
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Prepaid Expenses and Deposits	Note 3. Prepaid Expenses and Deposits The following summarizes the Company's prepaid expenses and deposits outstanding as at December 31, 2021 and 2020: Schedule of prepaid expenses 2021 2020 Rental deposit $ 1,050 $ 1,050 Deposit on February 11, 2022 shareholder meeting 24,945 — Total Prepaid Expenses and Deposits $ 25,995 $ 1,050

Intangible Assets

Intangible Assets	12 Months Ended
	Dec. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets	Note 4. Intangible Assets Intangible asset transactions are summarized as follows: Intangible asset transactions Patent Rights Patent Application Total Cost Balance, December 31, 2019 $ 30,000 $ 191,008 $ 221,008 Additions — 70,178 70,178 Balance, December 31, 2020 $ 30,000 $ 261,186 $ 291,186 Additions — 90,985 90,985 Balance, December 31, 2021 $ 30,000 $ 352,171 $ 382,171 Accumulated amortization Balance, December 31, 2019 $ 13,500 $ — $ 13,500 Amortization 3,000 — 3,000 Balance, December 31, 2020 $ 16,500 $ — $ 16,500 Amortization 3,000 — 3,000 Balance, December 31, 2021 $ 19,500 $ — $ 19,500 Net carrying amounts December 31, 2019 $ 16,500 $ 191,008 $ 207,508 December 31, 2020 $ 13,500 $ 261,186 $ 274,686 December 31, 2021 $ 10,500 $ 352,171 $ 362,671 During the year ended December 31, 2015, the Company entered into an Assignment of Patents and Patent Application (effective January 1, 2015) (the "Patent Assignment") with the Institut National des Sciences Appliquees de Rouen ("INSA") for the assignment of certain patents and all rights associated therewith (the "Patents"). The Company and INSA had previously entered into a licensing agreement for the Patents in August 2004. The Patent Assignment transfers all of the Patents and rights associated therewith to the Company upon payment to INSA in the sum of $ 30,000 (25,000 Euros) (paid). During the year ended December 31, 2021, the Company recorded $ 3,000 (2020 - $ 3,000 ) in amortization expense associated with the Patents Rights. During the year ended December 31, 2015, the Company entered into a Technology Transfer Agreement with Grant Young for the assignment of his 50% ownership of certain patents and all rights associated therewith (the "Patent Application Rights"). In exchange for the Patent Application Rights, the Company agreed to pay $ 10,000 (paid) and to issue 6,000,000 warrants (issued) to purchase shares of the Company's common stock at an exercise price of $0.10 per share for a period of five years. The Patent Application Rights had a total fair value of $35,000, which was allocated as $10,000 to the cash consideration paid, with the remaining $25,000 being allocated to the warrant component of the overall consideration. The Company incurred an additional $317,171 in direct costs relating to the Patent Application Rights, $ 90,985 of which were incurred during the year ended December 31, 2021. The remaining 50% ownership of the Patent Application Rights was acquired from the Governors of the University of Alberta in exchange for a future gross revenue royalty from any product developed as a result of research done at the University. During the year ended December 31, 2016, the Company entered into a Universal Assignment with Grant Young for the assignment of his ownership of certain new and useful improvements in an invention entitled "Use of Anti-Aging Glycoprotein for Enhancing Survival of Neurosensory Precursor Cells" (the "New Patent Application Rights"). In exchange for the New Patent Application Rights, the Company agreed to pay $1 (paid). The Company incurred $ 2,415 in direct costs relating to the New Patent Application Rights during the year ended December 31, 2016. No amortization was recorded on the Patent Application Rights or the New Patent Application Rights to December 31, 2021.

Stock Options

Stock Options	12 Months Ended
	Dec. 31, 2021
Stock Options
Stock Options	Note 5. Stock Options Pursuant to an amendment on April 6, 2020, the aggregate number of shares that may be issued under the 2017 Stock Option and Stock Bonus Plan (the “2017 Plan”) is 85,700,000 shares, subject to adjustment as provided therein. The 2017 Plan is administered by the Company’s Board of Directors, or a committee appointed by the Board of Directors, and includes two types of options. Options intended to qualify as incentive stock options under Section 422 of the Internal Revenue Code of 1986, as amended, are referred to as incentive options. Options that are not intended to qualify as incentive options are referred to as non-qualified options. The exercise price of an option may be paid in cash, in shares of the Company's common stock or other property having a fair market value equal to the exercise price of the option, or in a combination of cash, shares, other securities and property. As of December 31, 2021, there are 84,690,000 options granted and outstanding under the 2017 Plan. Stock option transactions are summarized as follows: Schedule of Share-based Compensation, Stock Options, Activity Number of Weighted Average Exercise Price Weighted Average Remaining Life $ (Years) Outstanding, December 31, 2019 91,450,000 0.14 Options cancelled (36,000,000 ) 0.13 Options exercised (3,200,000 ) 0.04 Options granted 30,400,000 0.13 Outstanding, December 31, 2020 82,650,000 0.15 4.06 Number of Weighted Average Exercise Price Weighted Average Remaining Life $ (Years) Outstanding, December 31, 2020 82,650,000 0.15 Options cancelled (76,100,000 ) 0.16 Options exercised (750,000 ) 0.07 Options granted 78,890,000 0.11 Outstanding, December 31, 2021 84,690,000 0.15 4.23 During the year ended December 31, 2021, the Company granted the following stock options: 500,000 options for shares of common stock exercisable at $0.18 per share, expiring April 15, 2027. 78,390,000 options for shares of common stock exercisable at $0.11 per share, expiring Aug 3, 2028 The CFO of the Company exercised 750,000 options for shares of common stock at $ 0.07 per share through a cashless exercise of the options resulting in 555,556 shares being issued. Total share-based compensation for the 78,890,000 stock options granted (2020 - 30,400,000 ) and vested during the year ended December 31, 2021 was $ 1,413,055 (2020 - $ 6,740,743 ). The fair values of the stock options granted were estimated using the Black-Scholes Option Pricing Model, based on the following weighted average assumptions: Schedule of valuation assumptions for options December 31, 2021 December 31, 2020 Risk-free interest rate 1.76 % 2.55 % Dividend yield 0.00 % 0.00 % Expected stock price volatility 140.70 % 143.56 % Expected forfeiture rate 0.00 % 0.00 % Expected life 6.00 years 5.09 years The following non-qualified stock options were outstanding and exercisable at December 31, 2021: Schedule of options by exercise price Expiry date Exercise Price Number of Options Number of $ December 31, 2022 0.06 800,000 800,000 August 31, 2023 0.08 600,000 600,000 November 8, 2023 0.09 4,000,000 4,000,000 May 5, 2026 0.11 150,000 150,000 October 26, 2026 0.10 500,000 500,000 November 27, 2026 0.10 250,000 250,000 August 3, 2028 0.11 74,500,000 74,500,000 August 3, 2028 0.11 3,890,000 1,945,000 84,690,000 82,745,000 As at December 31, 2021, the aggregate intrinsic value of the Company's stock options is $ 2,107,500 (December 31, 2020 – $ 393,710 ).

Warrants

Warrants	12 Months Ended
	Dec. 31, 2021
Warrants
Warrants	Note 6. Warrants Warrant transactions are summarized as follows: Schedule of Stockholders' Equity Note, Warrants or Rights Number of Weighted Average Exercise Price $ Outstanding, December 31, 2019 8,500,000 0.22 Warrants cancelled — — Warrants granted 1,826,857 0.07 Outstanding, December 31, 2020 10,326,857 0.19 Warrants granted 4,968,572 0.08 Warrants exercised (3,214,286 ) 0.07 Outstanding, December 31, 2021 12,081,143 0.17 The following warrants were outstanding and exercisable as at December 31, 2021: Schedule of outstanding and exercisable Number of Warrants Exercise Price Expiry Date 6,000,000 $ 0.26 July 14, 2024 833,333 0.12 October 15, 2022 250,000 0.12 October 21, 2022 116,667 0.12 November 1, 2022 83,334 0.12 November 12, 2022 216,666 0.12 December 18, 2022 110,714 0.07 March 1, 2022 142,571 0.07 March 1, 2022 359,286 0.07 March 1, 2022 100,000 0.07 March 1, 2022 442,857 0.07 March 1, 2022 571,429 0.07 March 1, 2022 100,000 0.07 March 1, 2022 500,000 0.07 March 1, 2022 100,000 0.07 March 1, 2022 357,143 0.07 March 1, 2022 357,143 0.07 March 1, 2022 1,440,000 0.10 March 1, 2022 12,081,143 On November 19, 2021, the board of directors of Protokinetix, Inc. Extended the expiration date of the warrant issued as follows: - Extended to the December offering and the August offering a total of 4,795,429 warrants to expire as of March 1, 2022 . The modifications to the warrants resulted in them meeting the definition of a derivative instrument under ASC 815 – Derivative and Hedging. They continue to be classified in equity as the number of shares and the exercise price were both fixed at inception. The extension of the term of the warrants resulted in additional value being attributed to those warrants. On November 19, 2021 the fair value of the warrants was estimated to be $ 19,227 using a Black Scholes Model. The Company recorded a deemed dividend of $ 19,227 in deficit related to the difference between the original and modified warrants.

Stockholders' Equity

Stockholders' Equity	12 Months Ended
	Dec. 31, 2021
Equity [Abstract]
Stockholders' Equity	Note 7. Stockholders' Equity The Company is authorized to issue 400,000,000 (December 31, 2020 – 400,000,000 ) shares of $ 0.0000053 par value common stock. Each holder of common stock has the right to one vote but does not have cumulative voting rights. Shares of common stock are not subject to any redemption or sinking fund provisions, nor do they have any preemptive, subscription or conversion rights. Holders of common stock are entitled to receive dividends whenever funds are legally available and when declared by the board of directors, subject to the prior rights of holders of all classes of stock outstanding having priority rights as to dividends. No dividends have been declared or paid as of December 31, 2021 (December 31, 2020 - $ 0 nil). During the year ended December 2021, the Company: a) Issued 3,528,572 units (each unit consisting of one share of common stock and one warrant to purchase one share of common stock $ 0.07 ) as part of a private placement for total proceeds of $ 247,000 . b) Issued 200,000 shares of common stock at $ 0.12 as part of a private placement for total proceeds of $ 24,000 . c) Issued 1,440,000 units (each unit consisting of one share of common stock and one warrant to purchase one share of common stock $ 0.10 ) as part of a private placement for total proceeds of $ 144,000 . d) Issued 3,214,286 shares of common stock from exercised warrants (2,214,286 shares issued at $0.07 and 1,000,000 shares issued at $0.12) for total proceeds of $ 275,000 . e) Issued 555,556 shares of common stock to CFO pursuant to a cashless exercise of 750,000 stock options. f) Issued 250,000 shares of common stock at $ 0.08 as part of a private placement for total proceeds of $ 20,000 . g Issued 2,250,000 shares of common stock at $ 0.06 as part of a private placement for total proceeds of $ 135,000 . h) Extended exercise date for warrants to purchase 1,440,000 shares of common stock issued August of 2021. i) Extended exercise date for warrants to purchase 3,355,429 shares of common stock, issued December of 2020. During the year ended December 2020, the Company: a) Issued 2,222,222 shares of common stock to investors at $ 0.09 per share for gross proceeds of $ 200,000 . b) Issued 320,513 shares of common stock to investors at $ 0.078 per share for gross proceeds of $ 25,001 . c) Issued 3,653,077 shares of common stock to investors at $ 0.065 per share for gross proceeds of $ 237,450 . d) Issued 2,532,143 shares of common stock to investors (one of which was the President and CEO of the Company) at $ 0.07 per share for gross proceeds of $ 177,250 . e) Issued 1,826,857 shares of common stock to investors at $ 0.07 per share for gross proceeds of $ 127,880 and the option to exercise a warrant for one additional share at $0.07, exercisable for one year.

Related Party Transactions and

Related Party Transactions and Balances	12 Months Ended
	Dec. 31, 2021
Related Party Transactions [Abstract]
Related Party Transactions and Balances	Note 8. Related Party Transactions and Balances During the twelve month period ended December 31, 2021 and 2020, the Company entered into the following related party transactions: a) Pursuant to a consulting agreement with an effective date of November 14, 2017, a total of $ 60,000 (2020 - $ 60,000 ) was paid or accrued to the Company's CFO. During the twelve months ended December 31, 2021, the Company reimbursed a company controlled by the CFO a total of $ 12,600 (2020 - $ 12,600 ) in office rent. b) On March 26, 2020, the Company cancelled and concurrently replaced 10,000,000 stock options and 1,000,000 stock options previously issued to the Company’s CEO and a Director of the Company in 2017, respectively. The 11,000,000 replacement options granted have a term of 6 years and are exercisable at a price of $ 0.14 per share, expiring on March 26, 2026 . The modification incremental fair value of $ 235,703 was recognized during the period. No stock options were issued during the three month period ending December 31, 2021. c) June 12, 2020, the Company cancelled 4,000,000 stock options previously issued in July 2019 to the Company’s CFO and replaced them with 3,500,000 stock options. The 3,500,000 replacement options granted have a term of 6 years and are exercisable at a price of $ 0.12 per share, expiring on June 11, 2026 . The modification incremental fair value of $ 5,704 was recognized in the period. d) On August 4, 2021, the Company cancelled and concurrently replaced 25,000,000 stock options previously issued to the Company’s CEO and a Director of the Company from 2018 to 2020. The modification incremental fair value of $ 311,500 was recognized in the current period. The 25,000,000 replacement options and 2,600,000 new options granted have a term of 6 years, exercisable at a price of $ 0.11 per share, expiring on August 3, 2028 . e) On August 4, 2021, the Company cancelled and concurrently replaced 7,500,000 stock options previously issued to the Company’s CFO and a Director of the Company from 2019 to 2020. The modification incremental fair value of $ 70,700 was recognized in the current period. The 7,500,000 replacement options and 260,000 new options granted have a term of 6 years, exercisable at a price of $ 0.11 per share, expiring on August 3, 2028 . f) On August 4, 2021, the Company cancelled and concurrently replaced 7,000,000 stock options previously issued to a Director of the Company from 2018 to 2020. The modification incremental fair value of $ 131,300 was recognized in the current period The 7,000,000 replacement options granted have a term of 6 years, exercisable at a price of $ 0.11 per share, expiring on August 3, 2028 . g) The Company recognized $ 722,822 including modification (2020 - $ 3,474,418 ) in share-based compensation during the period associated with stock options granted to key management personnel. The incremental fair value of modifications to stock options for key management was $ 72,322 . As at December 31, 2021 and December 31, 2020, there were $ 0 nil balances owing to related parties.

Commitments and Contingency

Commitments and Contingency	12 Months Ended
	Dec. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingency	Note 9. Commitments and Contingency Commitments As at December 31, 2021, the Company has the following commitments: a) Entered into a consulting agreement with an effective date of January 1, 2017 whereby the Company would pay the consultant $ 7,000 per month for providing research and development services b) Entered into a consulting agreement effective January 1, 2018, whereby the Company would pay the consultant $ 1,000 per month for a term of 1 year for providing public relations services, unless otherwise terminated by either party with at least 30 days’ notice. c) Entered into a consulting agreement effective April 1, 2019, whereby the Company would pay the consultant $ 1,500 per month minimum plus travel expenses for a term of 1 year for providing research consulting services. Agreement renews annually unless otherwise terminated by either party with at least 30 days’ notice. Contingency The Company was delinquent in filing certain income tax returns with the U.S. Internal Revenue Service and reports disclosing its interest in foreign bank accounts on form TDF 90-22.1, "Report of Foreign Bank and Financial Accounts" ("FBARs"). In September 2015, the Company filed the delinquent income tax returns and has sought waivers of any penalties under the IRS Offshore Voluntary Disclosure Program for late filing of the returns and FBARs. Under the program, the IRS has indicated that it will not impose a penalty for the failure to file delinquent income tax returns if there are no under reported tax liabilities. On November 30, 2017, the Company received a letter from the IRS concluding their review of the Company's tax returns under the program and accepting the returns as filed. No penalties have been assessed by the IRS to date, and management does not believe that the Company will incur any penalties relating to the tax years submitted under the program.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Income Taxes	Note 10. Income Taxes As a Nevada corporation, the Company is liable for taxes in the United States. As of December 31, 2021, the Company did not have any income for tax purposes and therefore, no tax liability or expense has been recorded in these financial statements (December 31, 2020 – none). A reconciliation of income taxes at statutory rates with the reported taxes is as follows: Schedule of Effective Income Tax Reconciliation 2021 2020 Net loss for the year $ (2,329,310 ) $ (7,644,490 ) Expected income tax recovery $ (490,000 ) $ (1,605,000 ) Non-deductible expenses $ 300,000 $ 1,416,000 Impact of change of future tax rate — — Adjustment to prior years provision versus statutory tax returns $ 90,000 $ 89,000 Change in valuation allowance — $ 100,000 Total income tax expense (recovery) $ — $ — The Company’s deferred tax assets that have not been recognized are as follows: Schedule of Deferred Tax Assets Tax benefit of net operating loss carry forward $ 6,300,000 $ 6,200,000 Valuation allowance $ (6,300,000 ) $ (6,200,000 ) $ — $ — The Company has tax losses of approximately $ 30,000,000 (December 31, 2020 - $ 29,000,000 ) to reduce future taxable income. The tax losses expire in years starting from 2021. The deferred tax asset associated with the tax loss carry forward is approximately $ 6,300,000 (December 31, 2020 - $ 6,200,000 ). The Company has provided a full valuation allowance against the deferred tax asset since it is more likely than not that the asset will not be realized. The difference between the Company's statutory income tax rate of ( 21 %) and its effective rate of zero is primarily attributable to the valuation allowance provided on deferred taxes arising from net operating loss carry forwards.

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2021
Subsequent Events [Abstract]
Subsequent Events	Note 11. Subsequent Events Subsequent to the year ended December 31, 2021, the Company: a) Between January 1, 2022 and February 8, 2022 the Company issued 2,136,666 shares of common stock to investors at $ 0.06 per share for gross proceeds of $ 128,200 . A Form D/A was filed on February 25, 2022. b) On February 11, 2022 the Company approved amending and restating of the Company’s articles of incorporation to increase the number of authorized shares from 400,000,000 to 500,000,000 of common stock.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying financial statements have been prepared by the Company in accordance with accounting principles generally accepted in the United States of America ("US GAAP") and are expressed in United States dollars.
Use of Estimates	Use of Estimates Preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. The more significant accounting estimates inherent in the preparation of the Company's financial statements include estimates as to valuation of equity- related instruments issued, deferred income taxes and the useful life and impairment of intangible assets.
Cash	Cash Cash consists of funds held in checking accounts. Cash balances may exceed federally insured limits from time to time.
Fair Value of Financial Instruments	Fair Value of Financial Instruments Financial instruments, which includes cash, accounts payable and accrued liabilities are carried at amortized cost, which management believes approximates fair value due to the short-term nature of these instruments. The Company measures the fair value of financial assets and liabilities pursuant to ASC 820 "Fair Value Measurements and Disclosures" which defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements. ASC 820 establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The policy describes three levels of inputs that may be used to measure fair value: Level 1 – quoted prices in active markets for identical assets or liabilities. Level 2 – quoted prices for similar assets and liabilities in active markets or inputs that are observable. Level 3 – inputs that are unobservable (for example cash flow modeling inputs based on assumptions). At December 31, 2021, there were no other assets or liabilities subject to additional disclosure.
Income Taxes	Income Taxes The Company accounts for income taxes following the assets and liability method in accordance with the ASC 740 "Income Taxes." Under such method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. The Company applies the accounting guidance issued to address the accounting for uncertain tax positions. This guidance clarifies the accounting for income taxes, by prescribing a minimum recognition threshold a tax position is required to meet before being recognized in the financial statements as well as provides guidance on derecognition, measurement, classification, interest and penalties, accounting in interim periods, disclosure and transition Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years that the asset is expected to be recovered or the liability settled.
Intangible assets – patent and patent application costs	Intangible assets – patent and patent application costs The Company owns intangible assets consisting of certain patents and patent applications. Intangible assets acquired separately are measured on initial recognition at cost. Following initial recognition, intangible assets are carried at cost less any accumulated amortization and any accumulated impairment losses. Subsequent expenditures are capitalized only when they increase the future economic benefits embodied in the specific asset to which they relate. All other expenditures are recognized in profit or loss as incurred. As at December 31, 2021, the Company does not hold any intangible assets with indefinite lives. Intangible assets with finite lives are amortized over the useful economic life and assessed for impairment whenever there is an indication that the intangible asset may be impaired. The amortization method and amortization period of an intangible asset with a finite life is reviewed at least annually. Changes in the expected useful life or the expected pattern of consumption of future economic benefits embodied in the asset is accounted for by changing the amortization period or method, as appropriate, and are treated as changes in accounting estimates. Amortization is recognized in profit or loss on a straight-line basis over the estimated useful lives of the Company's patents, whereas no amortization has been recognized on the patent application costs at December 31, 2021.
Research and Development Costs	Research and Development Costs Research and development costs are expensed as incurred.
Loss per Share and Potentially Dilutive Securities	Loss per Share and Potentially Dilutive Securities Basic loss per share is computed by dividing the net loss available to common stockholders by the weighted average number of common shares outstanding in the period. Diluted loss per share takes into consideration common shares outstanding (computed under basic earnings per share) and potentially dilutive securities. The effect of 84,690,000 stock options (December 31, 2020 – 82,650,000 ) and 12,081,143 warrants (December 31, 2020 – 10,326,857 ) were not included in the computation of diluted earnings per share for all periods presented because it was anti-dilutive due to the Company's losses.
Share-Based Compensation	Share-Based Compensation The Company has granted warrants and options to purchase shares of the Company's common stock to various parties for consulting services. The fair values of the warrants and options issued have been estimated using the Black-Scholes Option Pricing Model. The Company accounts for stock compensation with persons classified as employees for accounting purposes in accordance with ASC 718 "Compensation – Stock Compensation", which recognizes awards at fair value on the date of grant and recognition of compensation over the service period for awards expected to vest. Cliff Vesting is used and awards vest on the last day of the vesting period. The fair value of stock options is determined using the Black-Scholes Option Pricing Model. The fair value of common shares issued for services is determined based on the Company's stock price on the date of issuance. Share-based compensation for non-employees in exchange for goods and services used or consumed in an entity’s own operations are also recorded at fair value on the measurement date and accounted for in accordance with ASC 718. The measurement of share-based compensation is subject to periodic adjustment as the underlying instruments vest. The fair value of stock options is estimated using the Black-Scholes Option Pricing Model and the compensation charges are amortized over the vesting period.
Common stock	Common stock Common stock issued for non-monetary consideration are recorded at their fair value on the measurement date and classified as equity. The measurement date is defined as the earliest of the date at which the commitment for performance by the counterparty to earn the common shares is reached or the date at which the counterparty's performance is complete. Transaction costs directly attributable to the issuance of common stock, units and stock options are recognized as a deduction from equity, net of any tax effects.
Related Party Transactions	Related Party Transactions A related party is generally defined as (i) any person that holds 10% or more of the Company's securities and their immediate families, (ii) the Company's management, (iii) someone that directly or indirectly controls, is controlled by or is under common control with the Company, or (iv) anyone who can significantly influence the financial and operating decisions of the Company. A transaction is considered to be a related party transaction when there is a transfer of resources or obligations between related parties.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (“ASU 2019-12”), which simplifies the accounting for income taxes by removing certain exceptions related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The new ASU also simplifies aspects of the accounting for franchise taxes and enacted changes in tax laws or rates. These changes aim to improve the overall usefulness of disclosures to financial statement users and reduce unnecessary costs to companies when preparing the disclosures. The guidance was effective for the Company beginning on January 1, 2021 and prescribes different transition methods for the various provisions. The adoption of ASU 2019-12 did not have a material impact on the Company’s financial statements and related disclosures. Other than the above, the Company has determined that other significant newly issued accounting pronouncements are either not applicable to the Company’s business or that no material effect is expected on the financial statements as a result of future adoption.

Prepaid Expenses and Deposits (

Prepaid Expenses and Deposits (Tables)	12 Months Ended
	Dec. 31, 2021
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Schedule of prepaid expenses	Schedule of prepaid expenses 2021 2020 Rental deposit $ 1,050 $ 1,050 Deposit on February 11, 2022 shareholder meeting 24,945 — Total Prepaid Expenses and Deposits $ 25,995 $ 1,050

Intangible Assets (Tables)

Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible asset transactions	Intangible asset transactions Patent Rights Patent Application Total Cost Balance, December 31, 2019 $ 30,000 $ 191,008 $ 221,008 Additions — 70,178 70,178 Balance, December 31, 2020 $ 30,000 $ 261,186 $ 291,186 Additions — 90,985 90,985 Balance, December 31, 2021 $ 30,000 $ 352,171 $ 382,171 Accumulated amortization Balance, December 31, 2019 $ 13,500 $ — $ 13,500 Amortization 3,000 — 3,000 Balance, December 31, 2020 $ 16,500 $ — $ 16,500 Amortization 3,000 — 3,000 Balance, December 31, 2021 $ 19,500 $ — $ 19,500 Net carrying amounts December 31, 2019 $ 16,500 $ 191,008 $ 207,508 December 31, 2020 $ 13,500 $ 261,186 $ 274,686 December 31, 2021 $ 10,500 $ 352,171 $ 362,671

Stock Options (Tables)

Stock Options (Tables)	12 Months Ended
	Dec. 31, 2021
Stock Options
Schedule of Share-based Compensation, Stock Options, Activity	Schedule of Share-based Compensation, Stock Options, Activity Number of Weighted Average Exercise Price Weighted Average Remaining Life $ (Years) Outstanding, December 31, 2019 91,450,000 0.14 Options cancelled (36,000,000 ) 0.13 Options exercised (3,200,000 ) 0.04 Options granted 30,400,000 0.13 Outstanding, December 31, 2020 82,650,000 0.15 4.06 Number of Weighted Average Exercise Price Weighted Average Remaining Life $ (Years) Outstanding, December 31, 2020 82,650,000 0.15 Options cancelled (76,100,000 ) 0.16 Options exercised (750,000 ) 0.07 Options granted 78,890,000 0.11 Outstanding, December 31, 2021 84,690,000 0.15 4.23
Schedule of valuation assumptions for options	Schedule of valuation assumptions for options December 31, 2021 December 31, 2020 Risk-free interest rate 1.76 % 2.55 % Dividend yield 0.00 % 0.00 % Expected stock price volatility 140.70 % 143.56 % Expected forfeiture rate 0.00 % 0.00 % Expected life 6.00 years 5.09 years
Schedule of options by exercise price	Schedule of options by exercise price Expiry date Exercise Price Number of Options Number of $ December 31, 2022 0.06 800,000 800,000 August 31, 2023 0.08 600,000 600,000 November 8, 2023 0.09 4,000,000 4,000,000 May 5, 2026 0.11 150,000 150,000 October 26, 2026 0.10 500,000 500,000 November 27, 2026 0.10 250,000 250,000 August 3, 2028 0.11 74,500,000 74,500,000 August 3, 2028 0.11 3,890,000 1,945,000 84,690,000 82,745,000

Warrants (Tables)

Warrants (Tables)	12 Months Ended
	Dec. 31, 2021
Warrants
Schedule of Stockholders' Equity Note, Warrants or Rights	Schedule of Stockholders' Equity Note, Warrants or Rights Number of Weighted Average Exercise Price $ Outstanding, December 31, 2019 8,500,000 0.22 Warrants cancelled — — Warrants granted 1,826,857 0.07 Outstanding, December 31, 2020 10,326,857 0.19 Warrants granted 4,968,572 0.08 Warrants exercised (3,214,286 ) 0.07 Outstanding, December 31, 2021 12,081,143 0.17
Schedule of outstanding and exercisable	Schedule of outstanding and exercisable Number of Warrants Exercise Price Expiry Date 6,000,000 $ 0.26 July 14, 2024 833,333 0.12 October 15, 2022 250,000 0.12 October 21, 2022 116,667 0.12 November 1, 2022 83,334 0.12 November 12, 2022 216,666 0.12 December 18, 2022 110,714 0.07 March 1, 2022 142,571 0.07 March 1, 2022 359,286 0.07 March 1, 2022 100,000 0.07 March 1, 2022 442,857 0.07 March 1, 2022 571,429 0.07 March 1, 2022 100,000 0.07 March 1, 2022 500,000 0.07 March 1, 2022 100,000 0.07 March 1, 2022 357,143 0.07 March 1, 2022 357,143 0.07 March 1, 2022 1,440,000 0.10 March 1, 2022 12,081,143

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Schedule of Effective Income Tax Reconciliation	Schedule of Effective Income Tax Reconciliation 2021 2020 Net loss for the year $ (2,329,310 ) $ (7,644,490 ) Expected income tax recovery $ (490,000 ) $ (1,605,000 ) Non-deductible expenses $ 300,000 $ 1,416,000 Impact of change of future tax rate — — Adjustment to prior years provision versus statutory tax returns $ 90,000 $ 89,000 Change in valuation allowance — $ 100,000 Total income tax expense (recovery) $ — $ —
Schedule of Deferred Tax Assets	The Company’s deferred tax assets that have not been recognized are as follows: Schedule of Deferred Tax Assets Tax benefit of net operating loss carry forward $ 6,300,000 $ 6,200,000 Valuation allowance $ (6,300,000 ) $ (6,200,000 ) $ — $ —

Basis of Presentation _ Going_2

Basis of Presentation – Going Concern Uncertainties (Details Narrative) - USD ($)	1 Months Ended	12 Months Ended
	Nov. 19, 2021	Dec. 31, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Cash consideration		$ 30,000
Additional patent applications		$ 10,000
Warrant issued		6,000,000
Fair Value Adjustment of Warrants	$ 19,227	$ 25,000

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Details Narrative) - shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Warrant [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	12,081,143	10,326,857
Equity Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	84,690,000	82,650,000

Prepaid Expenses (Details)

Prepaid Expenses (Details) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Rental deposit	$ 1,050	$ 1,050
Deposit on February 11, 2022 shareholder meeting	24,945	0
Total Prepaid Expenses and Deposits	$ 25,995	$ 1,050

Intangible Assets (Details)

Intangible Assets (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Finite-Lived Intangible Assets [Line Items]
Beginning balance	$ 291,186	$ 221,008
Additions	90,985	70,178
Ending balance	382,171	291,186
Beginning balance	16,500	13,500
Amortization	3,000	3,000
Ending balance	19,500	16,500
Net carrying amounts	362,671	274,686	$ 207,508
Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Beginning balance	30,000	30,000
Additions	0	0
Ending balance	30,000	30,000
Beginning balance	16,500	13,500
Amortization	3,000	3,000
Ending balance	19,500	16,500
Net carrying amounts	10,500	13,500	16,500
Patent Application Rights [Member]
Finite-Lived Intangible Assets [Line Items]
Beginning balance	261,186	191,008
Additions	90,985	70,178
Ending balance	352,171	261,186
Beginning balance	0	0
Amortization	0	0
Ending balance	0	0
Net carrying amounts	$ 352,171	$ 261,186	$ 191,008

Intangible Assets (Details Narr

Intangible Assets (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2016	Dec. 31, 2015
Finite-Lived Intangible Assets [Line Items]
Payments to Acquire Intangible Assets	$ 90,985	$ 70,178
Amortization of Intangible Assets	3,000	$ 3,000
Additional patent applications				$ 10,000
Warrant issued				6,000,000
Grant Young [Member] | Technology Transfer Agreement [Member]
Finite-Lived Intangible Assets [Line Items]
Additional patent applications				$ 10,000
Warrant issued				6,000,000
Patent Application Rights [Member]
Finite-Lived Intangible Assets [Line Items]
Payments to Acquire Intangible Assets				$ 30,000
Direct Operating Costs	$ 90,985		$ 2,415

Stock Options (Details)

Stock Options (Details) - Equity Option [Member] - $ / shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding, beginning	82,650,000	91,450,000
Weighted average exercise price beginning balance	$ 0.15	$ 0.14
Options cancelled	(76,100,000)	(36,000,000)
Weighted Average Exercise Price, cancelled	$ 0.16	$ 0.13
Option exercised	(750,000)	(3,200,000)
Weighted Average Exercise Price, exercised	$ 0.07	$ 0.04
Options granted	78,890,000	30,400,000
Weighted Average Exercise Price, granted	$ 0.11	$ 0.13
Outstanding, ending	84,690,000	82,650,000
Weighed average exercise price ending balance	$ 0.15	$ 0.15
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term	4 years 2 months 23 days	4 years 21 days

Stock Options (Details 1)

Stock Options (Details 1)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Stock Options
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate	1.76%	2.55%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate	0.00%	0.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate	140.70%	143.56%
Expected forfeiture rate	0.00%	0.00%
Expected life	6 years	5 years 1 month 2 days

Stock Options (Details 2)

Stock Options (Details 2)	12 Months Ended
	Dec. 31, 2021$ / sharesshares
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number of outstanding	84,690,000
Number of options exercisable	82,745,000
Stock Option 1 [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Date	Dec. 31, 2022
Weighed average exercise price | $ / shares	$ 0.06
Number of outstanding	800,000
Number of options exercisable	800,000
Stock Option 2 [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Date	Aug. 31, 2023
Weighed average exercise price | $ / shares	$ 0.08
Number of outstanding	600,000
Number of options exercisable	600,000
Stock Option 3 [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Date	Nov. 8, 2023
Weighed average exercise price | $ / shares	$ 0.09
Number of outstanding	4,000,000
Number of options exercisable	4,000,000
Stock Option 4 [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Date	May 5, 2026
Weighed average exercise price | $ / shares	$ 0.11
Number of outstanding	150,000
Number of options exercisable	150,000
Stock Option 5 [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Date	Oct. 26, 2026
Weighed average exercise price | $ / shares	$ 0.10
Number of outstanding	500,000
Number of options exercisable	500,000
Stock Option 6 [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Date	Nov. 27, 2026
Weighed average exercise price | $ / shares	$ 0.10
Number of outstanding	250,000
Number of options exercisable	250,000
Stock Option 7 [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Date	Aug. 3, 2028
Weighed average exercise price | $ / shares	$ 0.11
Number of outstanding	74,500,000
Number of options exercisable	74,500,000
Stock Option 8 [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Date	Aug. 3, 2028
Weighed average exercise price | $ / shares	$ 0.11
Number of outstanding	3,890,000
Number of options exercisable	1,945,000

Stock Options (Details Narrativ

Stock Options (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number	82,745,000
Share-based Payment Arrangement, Expense	$ 78,890,000	$ 30,400,000
Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture	1,413,055	6,740,743
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value	$ 2,107,500	393,710
Common Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issuance of common stock pursuant to cashless option exercise, Shares	555,556
Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture
Equity Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options granted	84,690,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number	500,000
Option exercised	750,000	3,200,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price	$ 0.07	$ 0.04
Stock Option 1 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number	78,390,000

Warrants (Details)

Warrants (Details) - Warrant [Member] - $ / shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrant outstanding, beginning	10,326,857	8,500,000
Warrant weighted average exercise price, beginning	$ 0.19	$ 0.22
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Forfeitures and Expirations		0
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value		$ 0
Warrant granted	4,968,572	1,826,857
Warrant weighted average exercise price, granted	$ 0.08	$ 0.07
Warrant exercised	(3,214,286)
Warrant weighted average exercise price, exercised	$ 0.07
Warrant outstanding, ending	12,081,143	10,326,857
Warrant weighted average exercise price, ending	$ 0.17	$ 0.19

Warrants (Details 1)

Warrants (Details 1)	12 Months Ended
	Dec. 31, 2021$ / sharesshares
Warrant 1 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Class of Warrant or Right, Outstanding | shares	6,000,000
Warrant weighted average exercise price | $ / shares	$ 0.26
Expiry Date	July 14, 2024
Warrant 2 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Class of Warrant or Right, Outstanding | shares	833,333
Warrant weighted average exercise price | $ / shares	$ 0.12
Expiry Date	October 15, 2022
Warrant 3 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Class of Warrant or Right, Outstanding | shares	250,000
Warrant weighted average exercise price | $ / shares	$ 0.12
Expiry Date	October 21, 2022
Warrant 4 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Class of Warrant or Right, Outstanding | shares	116,667
Warrant weighted average exercise price | $ / shares	$ 0.12
Expiry Date	November 1, 2022
Warrant 5 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Class of Warrant or Right, Outstanding | shares	83,334
Warrant weighted average exercise price | $ / shares	$ 0.12
Expiry Date	November 12, 2022
Warrant 6 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Class of Warrant or Right, Outstanding | shares	216,666
Warrant weighted average exercise price | $ / shares	$ 0.12
Expiry Date	December 18, 2022
Warrant 7 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Class of Warrant or Right, Outstanding | shares	110,714
Warrant weighted average exercise price | $ / shares	$ 0.07
Expiry Date	March 1, 2022
Warrant 8 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Class of Warrant or Right, Outstanding | shares	142,571
Warrant weighted average exercise price | $ / shares	$ 0.07
Expiry Date	March 1, 2022
Warrant 9 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Class of Warrant or Right, Outstanding | shares	359,286
Warrant weighted average exercise price | $ / shares	$ 0.07
Expiry Date	March 1, 2022
Warrant 10 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Class of Warrant or Right, Outstanding | shares	100,000
Warrant weighted average exercise price | $ / shares	$ 0.07
Expiry Date	March 1, 2022
Warrant 11 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Class of Warrant or Right, Outstanding | shares	442,857
Warrant weighted average exercise price | $ / shares	$ 0.07
Expiry Date	March 1, 2022
Warrant 12 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Class of Warrant or Right, Outstanding | shares	571,429
Warrant weighted average exercise price | $ / shares	$ 0.07
Expiry Date	March 1, 2022
Warrant 13 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Class of Warrant or Right, Outstanding | shares	100,000
Warrant weighted average exercise price | $ / shares	$ 0.07
Expiry Date	March 1, 2022
Warrant 14 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Class of Warrant or Right, Outstanding | shares	500,000
Warrant weighted average exercise price | $ / shares	$ 0.07
Expiry Date	March 1, 2022
Warrant 15 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Class of Warrant or Right, Outstanding | shares	100,000
Warrant weighted average exercise price | $ / shares	$ 0.07
Expiry Date	March 1, 2022
Warrant 16 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Class of Warrant or Right, Outstanding | shares	357,143
Warrant weighted average exercise price | $ / shares	$ 0.07
Expiry Date	March 1, 2022
Warrant 17 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Class of Warrant or Right, Outstanding | shares	357,143
Warrant weighted average exercise price | $ / shares	$ 0.07
Expiry Date	March 1, 2022
Warrant 18 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Class of Warrant or Right, Outstanding | shares	1,440,000
Warrant weighted average exercise price | $ / shares	$ 0.10
Expiry Date	March 1, 2022

Warrants (Details Narrative)

Warrants (Details Narrative) - USD ($)	1 Months Ended	12 Months Ended
	Nov. 19, 2021	Dec. 31, 2021	Dec. 31, 2015
Short-term Debt [Line Items]
Payments for Repurchase of Warrants		$ 4,795,429
Expire date		Mar. 1, 2022
Fair Value Adjustment of Warrants	$ 19,227		$ 25,000
Black Scholes Model [Member]
Short-term Debt [Line Items]
Fair Value Adjustment of Warrants	$ 19,227

Stockholders' Equity (Details N

Stockholders' Equity (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Defined Benefit Plan Disclosure [Line Items]
Shares authorized	400,000,000	400,000,000
Common Stock, Par or Stated Value Per Share	$ 0.0000053	$ 0.0000053
Dividends Receivable	$ 0	$ 0
Stock Issued During Period, Shares, New Issues	555,556
Warrants to purchase	1,440,000	3,355,429
Warrant [Member]
Defined Benefit Plan Disclosure [Line Items]
Warrants exercised	3,214,286
Proceeds from Warrant Exercises	$ 275,000
Equity Option [Member]
Defined Benefit Plan Disclosure [Line Items]
Option exercised	750,000	3,200,000
Investors
Defined Benefit Plan Disclosure [Line Items]
Stock Issued During Period, Shares, New Issues	3,528,572
Share Price	$ 0.07
Stock Issued During Period, Value, New Issues	$ 247,000
Investors One [Member]
Defined Benefit Plan Disclosure [Line Items]
Stock Issued During Period, Shares, New Issues	200,000
Share Price	$ 0.12
Stock Issued During Period, Value, New Issues	$ 24,000
Investors Two [Member]
Defined Benefit Plan Disclosure [Line Items]
Stock Issued During Period, Shares, New Issues	1,440,000
Share Price	$ 0.10
Stock Issued During Period, Value, New Issues	$ 144,000
Investors Three [Member]
Defined Benefit Plan Disclosure [Line Items]
Stock Issued During Period, Shares, New Issues	250,000
Share Price	$ 0.08
Stock Issued During Period, Value, New Issues	$ 20,000
Investors Four [Member]
Defined Benefit Plan Disclosure [Line Items]
Stock Issued During Period, Shares, New Issues	2,250,000
Share Price	$ 0.06
Stock Issued During Period, Value, New Issues	$ 135,000
Investors Five [Member]
Defined Benefit Plan Disclosure [Line Items]
Stock Issued During Period, Shares, New Issues	2,222,222
Share Price	$ 0.09
Stock Issued During Period, Value, New Issues	$ 200,000
Investors Six [Member]
Defined Benefit Plan Disclosure [Line Items]
Stock Issued During Period, Shares, New Issues	320,513
Share Price	$ 0.078
Stock Issued During Period, Value, New Issues	$ 25,001
Investors Seven [Member]
Defined Benefit Plan Disclosure [Line Items]
Stock Issued During Period, Shares, New Issues	3,653,077
Share Price	$ 0.065
Stock Issued During Period, Value, New Issues	$ 237,450
Investors Eight [Member]
Defined Benefit Plan Disclosure [Line Items]
Stock Issued During Period, Shares, New Issues	2,532,143
Share Price	$ 0.07
Stock Issued During Period, Value, New Issues	$ 177,250
Investors Ten [Member]
Defined Benefit Plan Disclosure [Line Items]
Stock Issued During Period, Shares, New Issues	1,826,857
Share Price	$ 0.07
Stock Issued During Period, Value, New Issues	$ 127,880

Related Party Transactions an_2

Related Party Transactions and Balances (Details Narrative) - USD ($)	Aug. 04, 2021	Jun. 12, 2021	Jun. 12, 2020	Mar. 26, 2020	Dec. 31, 2021	Aug. 04, 2021	Dec. 31, 2020
Related Party Transaction [Line Items]
Related Party Transaction, Amounts of Transaction					$ 60,000		$ 60,000
Options granted			3,500,000		11,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term	6 years	6 years			6 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price	$ 0.11		$ 0.12		$ 0.14	$ 0.11
Options Expiration Date	Aug. 3, 2028		Jun. 11, 2026		Mar. 26, 2026
Modification incremental fair value option			$ 5,704	$ 235,703		$ 311,500
Replacement options	25,000,000
Share-based Payment Arrangement, Expense, after Tax					$ 722,822		3,474,418
Due to Related Parties, Current							0
Chief Financial Officer [Member]
Related Party Transaction [Line Items]
Increase (Decrease) in Due from Officers and Stockholders, Current					$ 12,600		$ 12,600
Chief Executiveand Director Officer [Member]
Related Party Transaction [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Forfeitures and Expirations			4,000,000	10,000,000
Stock option issued			3,500,000	1,000,000
stock options replaced	25,000,000
Stock option granted	2,600,000
C F O [Member]
Related Party Transaction [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Forfeitures and Expirations	7,500,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price	$ 0.11					$ 0.11
Options Expiration Date	Aug. 3, 2028
Modification incremental fair value option	$ 70,700
Stock option granted	260,000
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted	7,500,000
Director [Member]
Related Party Transaction [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Forfeitures and Expirations	7,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price	$ 0.11					$ 0.11
Options Expiration Date	Aug. 3, 2028
Modification incremental fair value option	$ 131,300
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted	7,000,000
Key Management [Member]
Related Party Transaction [Line Items]
Modification incremental fair value option	$ 72,322

Commitments and Contingency (De

Commitments and Contingency (Details Narrative) - USD ($)	Apr. 02, 2019	Jan. 02, 2018	Jan. 02, 2017	Dec. 31, 2021	Dec. 31, 2020
Defined Benefit Plan Disclosure [Line Items]
Research and Development Expense				$ 435,872	$ 527,291
Consultant [Member]
Defined Benefit Plan Disclosure [Line Items]
Research and Development Expense			$ 7,000
Marketing Expense		$ 1,000
Travel and Entertainment Expense	$ 1,500

Income Taxes (Details)

Income Taxes (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Net loss for the year	$ (2,329,310)	$ (7,644,490)
Expected income tax recovery	(490,000)	(1,605,000)
Non-deductible expenses	300,000	1,416,000
Impact of change of future tax rate	0	0
Adjustment to prior years provision versus statutory tax returns	90,000	89,000
Change in valuation allowance	0	100,000
Total income tax expense (recovery)	$ 0	$ 0

Income Taxes (Details 1)

Income Taxes (Details 1) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Deferred Tax Assets, Gross	$ 6,300,000	$ 6,200,000
Deferred Tax Assets, Valuation Allowance	(6,300,000)	(6,200,000)
Deferred Tax Assets, Net of Valuation Allowance	$ 0	$ 0

Income Taxes (Details Narrative

Income Taxes (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Effective Income Tax Rate Reconciliation, Nondeductible Expense, Impairment Losses, Amount	$ 30,000,000	$ 29,000,000
Deferred Tax Assets, Capital Loss Carryforwards	$ 6,300,000	$ 6,200,000
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent	21.00%

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($)	1 Months Ended	12 Months Ended
	Feb. 08, 2022	Dec. 31, 2021	Feb. 11, 2022
Subsequent Event [Line Items]
Stock Issued During Period, Shares, New Issues		555,556
Investors
Subsequent Event [Line Items]
Stock Issued During Period, Shares, New Issues		3,528,572
Share Price		$ 0.07
Stock Issued During Period, Value, New Issues		$ 247,000
Subsequent Event [Member] | Minimum [Member]
Subsequent Event [Line Items]
Common stock, shares authorized			400,000,000
Subsequent Event [Member] | Maximum [Member]
Subsequent Event [Line Items]
Common stock, shares authorized			500,000,000
Subsequent Event [Member] | Investors
Subsequent Event [Line Items]
Stock Issued During Period, Shares, New Issues	2,136,666
Share Price	$ 0.06
Stock Issued During Period, Value, New Issues	$ 128,200